GlassScriptPhysician profile
Salma Alvi
NPI 1437462991
$3,322.60
in general payments reported to CMS, 2019-2025
22 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $186 · 2021: $502 · 2022: $629 · 2023: $636 · 2024: $499 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $643.40 | 2019-2024 | Xarelto |
| Pfizer INC. | $454.51 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $266.14 | 2019-2024 | Ultomiris, Soliris |
| Mallinckrodt Hospital Products INC. | $221.92 | 2023-2025 | Terlivaz |
| Otsuka America Pharmaceutical, INC. | $197.55 | 2024-2025 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $194.79 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.55 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $171.39 | 2019-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $156.86 | 2019-2024 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.81 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2022 | |
| Glaxosmithkline, LLC. | $124.85 | 2019 | |
| Csl Behring | $122.96 | 2020-2023 | Kcentra |
| Neurocrine Biosciences, INC. | $68.69 | 2024-2025 | Ingrezza |
| Abbvie INC. | $57.32 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcresta Therapeutics, INC. | $55.09 | 2019-2023 | Relizorb |
| Mylan Specialty L.P. | $47.95 | 2021 | |
| Ferring Pharmaceuticals INC. | $23.19 | 2024 | Rebyota |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.43 | 2022 | |
| Merck Sharp & Dohme LLC | $18.34 | 2019 | |
| Janssen Biotech, INC. | $17.17 | 2022 | |
| Gilead Sciences, INC. | $14.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salma Alvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.